Piper Jaffray analyst Matt O'Brien says that while capital concerns are weighing on K2M Group (KTWO) shares, his cash burn analysis suggests that the company will not need to execute another capital raise. Further, the analyst notes two other spine companies that also experienced sales channel disruptions in recent years, NuVasive (NUVA) and Globus Medical (GMED), found a bottom three weeks after the disclosure. K2M is just over two weeks since sales disruption disclosure, he points out. Shares of NuVasive and Globus fully recovered the amount of the down move in seven and three months, respectively, O'Brien tells investors in a research note. He recommends buying shares of K2M at current levels and keeps an Overweight rating on the name with a $22 price target.